We found that APOE ɛ4 allele carriers (1) presented an earlier decline in episodic memory and were diagnosed with symptomatic AD a mean of 2 years before noncarriers, (2) exhibited earlier changes in AD biomarkers, and (3) showed differences in the topography of structural and functional brain changes. The gene discussed is APOE; the disease is Alzheimer disease.